LeafNLP Demos
Back to explore

Report #2881587

Received Jan 12, 2026

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
68 yrs
State
CO
Recovered
Unknown
Vaccinated
Jan 8, 2026
Onset
Jan 8, 2026
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS25L9A4—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

2nd dose longer than recommended interval; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 68-year-old female patient who received Herpes zoster (Shingrix) (batch number 5L9A4, expiry date 17-JUN-2027) for prophylaxis. Previously administered products included Shingrix (first dose was received on 01-JAN-2010). On 08-JAN-2026, the patient received the 2nd dose of Shingrix. On 08-JAN-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: 2nd dose longer than recommended interval).